132 related articles for article (PubMed ID: 30909984)
1. Is the conquest of Hepatitis C imminent?
Rivett L; Alexander G
Expert Rev Mol Med; 2019 Mar; 21():e3. PubMed ID: 30909984
[TBL] [Abstract][Full Text] [Related]
2. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
3. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
4. Impact of host and virus genome variability on HCV replication and response to interferon.
Schweitzer CJ; Liang TJ
Curr Opin Virol; 2013 Oct; 3(5):501-7. PubMed ID: 23835049
[TBL] [Abstract][Full Text] [Related]
5. New perspectives in HCV therapy: entry inhibitors.
Donia M; Cacopardo B; Libra M; Scalia G; McCubrey JA; Nicoletti F
Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):181-94. PubMed ID: 20497122
[TBL] [Abstract][Full Text] [Related]
6. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
Zhao Q; Xia N
Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
[No Abstract] [Full Text] [Related]
7. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.
Georgel P; Schuster C; Zeisel MB; Stoll-Keller F; Berg T; Bahram S; Baumert TF
Trends Mol Med; 2010 Jun; 16(6):277-86. PubMed ID: 20537953
[TBL] [Abstract][Full Text] [Related]
8. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
9. Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies.
Ramanan V; Trehan K; Ong ML; Luna JM; Hoffmann HH; Espiritu C; Sheahan TP; Chandrasekar H; Schwartz RE; Christine KS; Rice CM; van Oudenaarden A; Bhatia SN
Virology; 2016 Jul; 494():236-47. PubMed ID: 27128351
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus: From Obscurity to the Lasker.
Liang TJ
Gastroenterology; 2016 Dec; 151(6):1052-1053. PubMed ID: 27765691
[No Abstract] [Full Text] [Related]
11. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
12. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
[TBL] [Abstract][Full Text] [Related]
13. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
[TBL] [Abstract][Full Text] [Related]
14. Development of novel treatments for hepatitis C.
Webster DP; Klenerman P; Collier J; Jeffery KJ
Lancet Infect Dis; 2009 Feb; 9(2):108-17. PubMed ID: 19179226
[TBL] [Abstract][Full Text] [Related]
15. Benzohydroxamic acids as potent and selective anti-HCV agents.
Kozlov MV; Kleymenova AA; Romanova LI; Konduktorov KA; Smirnova OA; Prasolov VS; Kochetkov SN
Bioorg Med Chem Lett; 2013 Nov; 23(21):5936-40. PubMed ID: 24035094
[TBL] [Abstract][Full Text] [Related]
16. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
Helmy A
Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
[TBL] [Abstract][Full Text] [Related]
17. A cyclic peptide mimic of an RNA recognition motif of human La protein is a potent inhibitor of hepatitis C virus.
Manna AK; Kumar A; Ray U; Das S; Basu G; Roy S
Antiviral Res; 2013 Mar; 97(3):223-6. PubMed ID: 23291201
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
20. New targets for treatment against HCV infection.
Pan Q; van der Laan LJ
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):505-15. PubMed ID: 23199508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
